Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations

被引:241
作者
Hamdy, Samar [1 ]
Haddadi, Azita [2 ]
Hung, Ryan W. [3 ]
Lavasanifar, Afsaneh [1 ,4 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Dent Pharm Ctr 3133, Edmonton, AB T6G 2N8, Canada
[2] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 0W0, Canada
[3] Univ Alberta, Fac Med, Dept Radiol & Diagnost Imaging, Edmonton, AB T6G 2N8, Canada
[4] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB T6G 2N8, Canada
关键词
Adjuvant; Cancer; Vaccine; PLGA; POLY(D; L-LACTIC-CO-GLYCOLIC ACID) MICROSPHERES; ANTIGEN CROSS-PRESENTATION; MACROPHAGES IN-VITRO; OF-THE-ART; IMMUNE-RESPONSES; BIODEGRADABLE MICROSPHERES; MELANOMA PATIENTS; TUMOR-IMMUNOTHERAPY; T-CELLS; PHASE-I;
D O I
10.1016/j.addr.2011.05.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Development of safe and effective cancer vaccine formulation is a primary focus in the field of cancer immunotherapy. The recognition of the crucial role of dendritic cells (DCs) in initiating anti-tumor immunity has led to the development of several strategies that target vaccine antigens to DCs as an attempt for developing potent, specific and lasting anti-tumor T cell responses. The main objective of this review is to provide an overview on the application of poly (D,L-lactic-co-glycolic acid) nanoparticles (PLGA-NPs) as cancer vaccine delivery system and highlight their potential in the development of future therapeutic cancer vaccines. PLGA-NPs containing antigens along with immunostimulatory molecules (adjuvants) can not only target antigen actively to DCs, but also provide immune activation and rescue impaired DCs from tumor-induced immuosupression. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:943 / 955
页数:13
相关论文
共 139 条
[1]   A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines [J].
Acharya, Abhinav P. ;
Clare-Salzler, Michael J. ;
Keselowsky, Benjamin G. .
BIOMATERIALS, 2009, 30 (25) :4168-4177
[2]   Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens [J].
Ackerman, AL ;
Kyritsis, C ;
Tampé, R ;
Cresswell, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (22) :12889-12894
[3]   BIODEGRADABLE MICROSPHERES AS CONTROLLED-RELEASE TETANUS TOXOID DELIVERY SYSTEMS [J].
ALONSO, MJ ;
GUPTA, RK ;
MIN, C ;
SIBER, GR ;
LANGER, R .
VACCINE, 1994, 12 (04) :299-306
[4]   Strategies for vaccine delivery - Preface [J].
Alpar, HO .
JOURNAL OF DRUG TARGETING, 2004, 11 (8-10) :459-461
[5]   Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro [J].
Audran, R ;
Peter, K ;
Dannull, J ;
Men, Y ;
Scandella, E ;
Groettrup, M ;
Gander, B ;
Corradin, G .
VACCINE, 2003, 21 (11-12) :1250-1255
[6]   PLGA nanoparticles in drug delivery: The state of the art [J].
Bala, I ;
Hariharan, S ;
Kumar, MNVR .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (05) :387-422
[7]  
Banchereau J, 2001, CANCER RES, V61, P6451
[8]   EFFECTIVE TUMOR-IMMUNOTHERAPY DIRECTED AGAINST AN ONCOGENE-ENCODED PRODUCT USING A VACCINIA VIRUS VECTOR [J].
BERNARDS, R ;
DESTREE, A ;
MCKENZIE, S ;
GORDON, E ;
WEINBERG, RA ;
PANICALI, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (19) :6854-6858
[9]   Toll-dependent selection of microbial antigens for presentation by dendritic cells [J].
Blander, JM ;
Medzhitov, R .
NATURE, 2006, 440 (7085) :808-812
[10]   Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes [J].
Bousso, P ;
Robey, E .
NATURE IMMUNOLOGY, 2003, 4 (06) :579-585